Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,308 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Biological Markers Clear all

Conditions: Sepsis, Acute Infection
Interventions: Not listed
Lead sponsor: MeMed Diagnostics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: New York, New York • Milwaukee, Wisconsin

Conditions: Posttraumatic Stress Disorder
Interventions: imaginal therapy, exercise, self-care; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Fort Hood, Texas

Conditions: Adnexal Mass
Interventions: Not listed
Lead sponsor: Fujirebio Diagnostics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Wilmington, North Carolina • Oklahoma City, Oklahoma

Conditions: Breast Neoplasms
Interventions: Physical activity; Behavioral
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Amyotrophic Lateral Sclerosis, ALS
Interventions: Edaravone (Radicava®/Radicava ORS®); Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 19
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 14 more

Conditions: Carcinoma, Squamous Cell
Interventions: VTX-2337, Nivolumab; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 12
States / cities: Birmingham, Alabama • Boston, Massachusetts • St Louis, Missouri + 4 more

Conditions: Prostate Cancer
Interventions: Physical Activity; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 45 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive
Interventions: Ocrelizumab, Lumbar Puncture, Methyloprednisolone, Antihistamine; Drug · Procedure
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 12
States / cities: Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: HPV Infections
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older · Female only
Enrollment: 197 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hepatocellular Carcinoma
Interventions: Lipiodol; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Neoplasms, Tumors, Solid Tumors, Metastatic Cancer
Interventions: EGFRBi-armed autologous activated T cells; Biological
Lead sponsor: Roger Williams Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Renal Cell Carcinoma
Interventions: Brivanib alaninate, Polymerase chain reaction, Iodine I 124 chimeric monoclonal antibody G250, Positron emission tomography/computed tomography, Protein expression analysis, Immunohistochemistry; Drug · Genetic · Other + 1 more
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Myotonic Dystrophy Type 2, Myotonic Dystrophy Type 1
Interventions: Non-interventional study; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 30 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Disseminated Neuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Stage 4S Neuroblastoma
Interventions: diagnostic laboratory biomarker analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Not listed
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Monrovia, California

Conditions: Prostate Cancer
Interventions: Vitamin E; Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Cardiovascular (CV) Risk
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 19 Years to 45 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: PTSD, Posttraumatic Stress Disorder
Interventions: RETeval; Device
Lead sponsor: VA Puget Sound Health Care System; Federal
Eligibility: 21 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sickle Cell Disease, HEMOGLOBIN SS, Hemoglobin S Beta-0 Thalassemia, Inflammation, Quality of Life
Interventions: Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA), Placebo Capsules; Dietary Supplement · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 10 Years to 19 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Sarcoidosis
Interventions: Acthar gel; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Actinic Keratosis
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer
Interventions: Broccoli sprout extract, Mango juice; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Not listed
Lead sponsor: MedImmune LLC; Industry
Eligibility: 40 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 9
States / cities: Baltimore, Maryland • Springfield, Massachusetts • St Louis, Missouri + 6 more

Conditions: Pelizaeus-Merzbacher Disease
Interventions: Not listed
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 6 Months to 17 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 3
States / cities: Atlanta, Georgia • Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Pancreatic Disease
Interventions: ChiRhoStim, Placebo; Drug
Lead sponsor: ChiRhoClin, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

A Multicenter Prospective Observational Study to Derive and Verify the Performance of a Host-response Based Diagnostic Tool for Early Detection of Severe Infections.

The Role of Exercise in the Treatment of PTSD Symptoms

New Biomarkers Evaluating Ovarian Cancer

Exercise in Women at Risk for Breast Cancer

Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

Evaluating Race Specific AGE Accumulation As a Behavioral Biomarker Prostate Cancer Survivors

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

A Study to Identify Markers in Blood and Tissue of HPV Clearance

Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors

Brivanib Metastatic Renal Cell Carcinoma

Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2

Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma

Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer

Geospatial Analysis of Neighborhood Environmental Stress in Relation to Biological Markers of Cardiovascular Health and Health Behaviors in Women

Biomarkers in the Retina for Prognosticating Mental Health Treatments

A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)

Use of CXCL9 as a Biomarker of Acthar Efficacy

Biomarker Database Registry for Photodynamic Therapy

Study to Evaluate the Effect of Sulforaphane in Broccoli Sprout Extract on Breast Tissue

A Study to Evaluate Biomarkers in Chronic Obstructive Pulmonary Disease

Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Pelizaeus-Merzbacher Disease

A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers